Orphazyme A/S (ORPHA.CO)

DKK 1120.0

(-2.61%)

Operating Expenses Summary of Orphazyme A/S

Orphazyme A/S's latest annual operating expenses in 2023 was 27.04 Thousand DKK , down -99.93% from previous year.
Orphazyme A/S's latest quarterly operating expenses in 2024 Q2 was -847.00 DKK , down 0.0% from previous quarter.
Orphazyme A/S reported a annual operating expenses of 40.45 Million DKK in annual operating expenses 2022, down -93.96% from previous year.
Orphazyme A/S reported a annual operating expenses of 669.49 Million DKK in annual operating expenses 2021, up 10.02% from previous year.
Orphazyme A/S reported a quarterly operating expenses of -847.00 DKK for 2024 Q2, down 0.0% from previous quarter.
Orphazyme A/S reported a quarterly operating expenses of 14.2 Million DKK for 2023 Q4, up 202857.14% from previous quarter.

Annual Operating Expenses Chart of Orphazyme A/S (2023 - 2015)

Historical Annual Operating Expenses of Orphazyme A/S (2023 - 2015)

Year	Operating Expenses	Operating Expenses Growth
2023	27.04 Thousand DKK	-99.93%
2022	40.45 Million DKK	-93.96%
2021	669.49 Million DKK	10.02%
2020	608.53 Million DKK	81.14%
2019	335.95 Million DKK	45.03%
2018	231.65 Million DKK	76.78%
2017	131.04 Million DKK	106.3%
2016	63.52 Million DKK	19.66%
2015	53.08 Million DKK	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q1	-847.00 DKK	-100.01%
2024 Q2	-847.00 DKK	0.0%
2023 Q4	14.2 Million DKK	202857.14%
2023 Q3	7000.00 DKK	-99.95%
2023 Q1	6417.00 DKK	-99.95%
2023 Q2	12.83 Million DKK	199900.0%
2023 FY	27.04 Million DKK	-33.16%
2022 Q1	13.64 Thousand DKK	-99.99%
2022 Q4	12.12 Million DKK	0.0%
2022 FY	40.45 Million DKK	-93.96%
2022 Q2	27.29 Million DKK	199914.66%
2021 Q1	28.67 Thousand DKK	-99.99%
2021 FY	669.49 Million DKK	10.02%
2021 Q3	81.14 Thousand DKK	-99.98%
2021 Q4	200.04 Million DKK	246442.44%
2021 Q2	404.73 Million DKK	1411514.12%
2020 Q1	122.77 Thousand DKK	-99.93%
2020 FY	608.53 Million DKK	81.14%
2020 Q4	360.03 Million DKK	191641.94%
2020 Q3	187.76 Thousand DKK	-99.92%
2020 Q2	243.3 Million DKK	198068.22%
2019 Q1	82.52 Thousand DKK	34.37%
2019 Q3	85.88 Thousand DKK	-99.95%
2019 Q2	162.98 Million DKK	197397.79%
2019 Q4	169.16 Million DKK	196857.67%
2019 FY	335.95 Million DKK	45.03%
2018 Q3	61.41 Thousand DKK	12.23%
2018 Q4	61.41 Thousand DKK	0.0%
2018 Q2	54.72 Thousand DKK	0.0%
2018 FY	231.65 Million DKK	76.78%
2018 Q1	54.72 Thousand DKK	43.63%
2017 Q2	27.42 Thousand DKK	0.0%
2017 Q3	38.09 Thousand DKK	38.94%
2017 Q4	38.09 Thousand DKK	0.0%
2017 FY	131.04 Million DKK	106.3%
2017 Q1	27.42 Thousand DKK	67.05%
2016 Q4	16.41 Thousand DKK	0.0%
2016 FY	63.52 Million DKK	19.66%
2016 Q2	15.26 Thousand DKK	0.0%
2016 Q1	15.26 Thousand DKK	0.0%
2016 Q3	16.41 Thousand DKK	7.51%
2015 FY	53.08 Million DKK	0.0%

Peer Operating Expenses Comparison of Orphazyme A/S

Name	Operating Expenses	Operating Expenses Difference
ALK-Abelló A/S	2.36 Billion DKK	99.999%
Bavarian Nordic A/S	3.02 Billion DKK	99.999%
Genmab A/S	10.92 Billion DKK	100.0%
Gubra A/S	164.35 Million DKK	99.984%
Novo Nordisk A/S	93.92 Billion DKK	100.0%
Pharma Equity Group A/S	24.81 Million DKK	99.891%
Zealand Pharma A/S	226.92 Million DKK	99.988%